by MM360 Staff | Jun 1, 2025 | Uncategorized
Source: CureToday articles Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– advanced breast cancer. Read More
by MM360 Staff | Jun 1, 2025 | Uncategorized
Source: CureToday articles Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer. Read More
by MM360 Staff | May 31, 2025 | Uncategorized
Source: ASCO Daily News Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell...
by MM360 Staff | May 31, 2025 | Uncategorized
Source: CureToday articles Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when compared with Faslodex. Read More
by MM360 Staff | May 31, 2025 | Uncategorized
Source: CureToday articles Second-line Enhertu improved key survival end points versus Cyramza plus paclitaxel for HER2+ gastric cancer or gastroesophageal junction adenocarcinoma. Read More
by MM360 Staff | May 31, 2025 | Uncategorized
Source: CureToday articles Trodelvy plus Keytruda, when given in the frontline, extended survival without progression versus chemo plus Keytruda in PD-L1+ metastatic TNBC. Read More
